잠시만 기다려 주세요. 로딩중입니다.

Filtering through the role of NRF2 in kidney disease

Archives of Pharmacal Research 2020년 43권 3호 p.361 ~ 369
 ( Schmidlin Cody J. ) - University of Arizona Department of Pharmacology and Toxicology

 ( Dodson Matthew B. ) - University of Arizona Department of Pharmacology and Toxicology
 ( Zhang Donna D. ) - University of Arizona Department of Pharmacology and Toxicology

Abstract


Kidney disease affects ~?10% of the population worldwide, resulting in millions of deaths each year. Mechanistically, oxidative stress is a major driver of various kidney diseases, and promotes the progression from acute to chronic injury, as well as renal cancer development. NRF2, the master regulator of redox balance, has been shown to protect against kidney disease through its negation of reactive oxygen species (ROS). However, many kidney diseases exhibit high levels of ROS as a result of decreased NRF2 protein levels and transcriptional activity. Many studies have tested the strategy of using NRF2 inducing compounds to alleviate ROS to prevent or slow down the progression of kidney diseases. Oppositely, in specific subsets of renal cancer, NRF2 is constitutively activated and contributes to tumor burden and overall poor prognosis; therefore, there has been a recent interest in studies investigating the benefits of NRF2 inhibition. In this review, we summarize recent literature investigating the role of NRF2 and oxidative stress in various kidney diseases, and how pharmacological modification of NRF2 signaling could play a protective role.

키워드

NRF2; KEAP1; Oxidative stress; Kidney disease; Renal cell carcinoma; Hypertension
원문 및 링크아웃 정보
 
등재저널 정보
SCI(E)
MEDLINE
KCI